ALLOGENE THERAPEUTICS INC (ALLO)
US0197701065 - Common Stock
| MRQ (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 51.24M | 83.16M | 61.90M | 173.30M | 183.40M | |||
| Marketable Securities | 240.32M | 365.54M | 455.40M | 284.00M | 644.60M | |||
| Receivables | N/A | 1.70M | 1.80M | 1.90M | 2.80M | |||
| Other Current Assets | 12.85M | 8.72M | 9.70M | 12.10M | 14.40M | |||
| Total Current Assets | 304.42M | 459.12M | 528.80M | 471.30M | 845.10M | |||
| Non-Current Assets | ||||||||
| PPE Net | 135.30M | 163.18M | 196.40M | 181.00M | 160.10M | |||
| Investments And Advances | 111.82M | 3.65M | 72.00M | 370.20M | 207.90M | |||
| Intangibles | N/A | N/A | N/A | N/A | 0.00 | |||
| Other Non-Current Assets | 37.58M | 16.90M | 19.90M | 16.10M | 14.60M | |||
| Total Non-Current Assets | 284.70M | 183.72M | 288.30M | 567.30M | 382.70M | |||
| TOTAL ASSETS | 589.12M | 642.84M | 817.10M | 1.04B | 1.23B | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 27.07M | 31.10M | 39.70M | 37.50M | 44.90M | |||
| Accounts Payable | 5.51M | 5.90M | 13.90M | 10.30M | 10.40M | |||
| Other Current Liabilities | N/A | 86.00K | 900.00K | 400.00K | 39.00M | |||
| Total Current Liabilities | 32.57M | 37.08M | 54.50M | 48.20M | 94.30M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 92.80M | 93.53M | 96.70M | 74.10M | 53.90M | |||
| Total Non-Current Liabilities | 92.80M | 93.53M | 96.70M | 74.00M | 53.90M | |||
| TOTAL LIABILITIES | 125.37M | 130.60M | 151.20M | 122.20M | 148.20M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -1.76B | -1.56B | -1.24B | -903.30M | -646.30M | |||
| Additional Paid In Capital | 2.22B | 2.08B | 1.91B | 1.82B | 1.73B | |||
| Common Shares | 210.00K | 169.00K | 100.00K | 100.00K | 100.00K | |||
| Other Shareholders' Equity | 157.00K | -955.00K | -9.90M | -2.60M | 300.00K | |||
| Shares Outstanding | 209.50M | 168.64M | 144.40M | 142.60M | 140.50M | |||
| Tangible Book Value per Share | 2.21 | 3.04 | 4.61 | 6.43 | 7.68 | |||
| Total Shareholders' Equity | 463.75M | 512.23M | 665.90M | 916.40M | 1.08B | |||
| TOTAL LIABILITIES AND EQUITY | 589.12M | 642.84M | 817.10M | 1.04B | 1.23B | |||
| Statistics | ||||||||
| Current Ratio | 9.35 | 12.38 | 9.70 | 9.78 | 8.96 | |||
| Return On Assets (ROA) | -89.10% | -50.91% | -40.71% | -24.75% | -20.38% | |||
| Return On Equity (ROE) | -113.19% | -63.89% | -49.95% | -28.05% | -23.18% | |||
All data in USD , ROIC based on taxRate of 0.21